$47.340
+0.279 (+0.59%)Al cierre
Noticias de VRNS
Eventos de VRNS
Rosenblatt Downgrades Varonis to Neutral, Price Target Cut to $49.75
Rosenblatt downgraded Varonis to Neutral from Buy with a price target of $49.75, down from $55, after the company entered into an agreement to be acquired by Proofpoint, a portfolio company of Thoma Bravo, in an all-cash transaction valued at $6.3B or $49.75 per share in cash. The firm views the deal as a "reasonable" outcome for shareholders. It expects the takeout to go through.
B. Riley Downgrades Varonis to Neutral, Price Target Cut to $49.75
B. Riley analyst Erik Suppiger downgraded Varonis to Neutral from Buy with a price target of $49.75, down from $55. The company announced it agreed to be acquired by Thoma Bravo-owed Proofpoint for $49.75/share in cash. The deal validates the strategic value of data security as AI adoption expands, especially for securing agentic AI, the analyst tells investors in a research note.
Wedbush Raises Varonis Price Target to $49.75
Wedbush raised the firm's price target on Varonis to $49.75 from $46 and keeps a Neutral rating on the shares. Proofpoint, a human and agent cybersecurity firm and a portfolio company of Thoma Bravo, entered into a definitive agreement to acquire Varonis in an all-cash deal valued at roughly $6.3B. Wedbush views a competitive bid as unlikely.
Wells Fargo Downgrades Varonis to Equal Weight, Price Target Cut to $49.75
Wells Fargo analyst Richard Poland downgraded Varonis to Equal Weight from Overweight with a price target of $49.75, down from $53, after the company announced it agreed to be acquired by Thoma Bravo-owed Proofpoint for $49.75/share in cash, expected to close in the first half of 2027 subject to approvals. With the deal officially announced and Wells' view it likely goes through, the firm moves to the sidelines.
TD Cowen Downgrades Varonis to Hold, Price Target Cut to $49.75
TD Cowen downgraded Varonis to Hold from Buy with a price target of $49.75, down from $56, after the company agreed to be acquired by Proofpoint, a Thoma Bravo portfolio company, for $49.75 per share. TD expects the transaction to close.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.